NCT05446129View on ClinicalTrials.gov

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

August 11, 2023

Study Completion Date

November 8, 2023

Conditions
Colorectal Cancer
Interventions
DRUG

Ezabenlimab

Ezabenlimab

DRUG

BI 765063

BI 765063

DRUG

Pembrolizumab

Pembrolizumab

Trial Locations (1)

10029

Mount Sinai School of Medicine, New York

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05446129 - A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery | Biotech Hunter | Biotech Hunter